FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307029582> ?p ?o ?g. }

• W4307029582 endingPage "2142" @default.
• W4307029582 startingPage "2134" @default.
• W4307029582 abstract "Purpose: This meta-analysis investigates the incidence of intraocular inflammation (IOI) after intravitreal antivascular endothelial growth factor injections in neovascular age-related macular degeneration. Methods: A systematic search was performed on Ovid MEDLINE, Embase, and Cochrane Central from January 2005 to April 2021. Randomized controlled trials comparing IOI after intravitreal bevacizumab, ranibizumab, brolucizumab, or aflibercept in neovascular age-related macular degeneration were included. Primary outcomes were sight-threatening IOI, final best-corrected visual acuity, and change in best-corrected visual acuity from baseline. Secondary outcomes included the incidence of other IOI events. Meta-analysis was performed using a random-effects model. Results: Overall, 11,460 unique studies were screened, of which 14 randomized controlled trials and 6,759 eyes at baseline were included. There was no difference between agents for the risk of endophthalmitis and retinal vascular occlusion. Compared with aflibercept, brolucizumab had a higher incidence of generalized IOI (risk ratio = 6.24, 95% confidence interval = [1.40–27.90]) and vitreous haze/floaters (risk ratio = 1.64, 95% confidence interval = [1.00–2.67]). There were no significant differences between comparators for other secondary end points. Conclusion: There was no difference in the risk of severe sight-threatening IOI outcomes between intravitreal antivascular endothelial growth factor agents. There was a significantly higher risk of generalized IOI after brolucizumab relative to aflibercept. Our results alongside other recent safety findings suggest the need for further investigation in the risk–benefit profile of brolucizumab for the treatment of neovascular age-related macular degeneration." @default.
• W4307029582 created "2022-10-22" @default.
• W4307029582 creator A5017733623 @default.
• W4307029582 creator A5034211616 @default.
• W4307029582 creator A5035642316 @default.
• W4307029582 creator A5042226622 @default.
• W4307029582 creator A5049876235 @default.
• W4307029582 date "2022-11-01" @default.
• W4307029582 modified "2023-10-17" @default.
• W4307029582 title "RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS" @default.
• W4307029582 cites W1500728559 @default.
• W4307029582 cites W1782061354 @default.
• W4307029582 cites W1968189763 @default.
• W4307029582 cites W2020732840 @default.
• W4307029582 cites W2053567993 @default.
• W4307029582 cites W2059547624 @default.
• W4307029582 cites W2154073405 @default.
• W4307029582 cites W2165010366 @default.
• W4307029582 cites W2170468054 @default.
• W4307029582 cites W2287587792 @default.
• W4307029582 cites W2619267093 @default.
• W4307029582 cites W2806212448 @default.
• W4307029582 cites W2939023004 @default.
• W4307029582 cites W2963553144 @default.
• W4307029582 cites W2970684805 @default.
• W4307029582 cites W2987790686 @default.
• W4307029582 cites W3005564888 @default.
• W4307029582 cites W3017504588 @default.
• W4307029582 cites W3035836792 @default.
• W4307029582 cites W3101908837 @default.
• W4307029582 cites W3101914433 @default.
• W4307029582 cites W3157686683 @default.
• W4307029582 doi "https://doi.org/10.1097/iae.0000000000003582" @default.
• W4307029582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36269802" @default.
• W4307029582 hasPublicationYear "2022" @default.
• W4307029582 type Work @default.
• W4307029582 citedByCount "8" @default.
• W4307029582 countsByYear W43070295822022 @default.
• W4307029582 countsByYear W43070295822023 @default.
• W4307029582 crossrefType "journal-article" @default.
• W4307029582 hasAuthorship W4307029582A5017733623 @default.
• W4307029582 hasAuthorship W4307029582A5034211616 @default.
• W4307029582 hasAuthorship W4307029582A5035642316 @default.
• W4307029582 hasAuthorship W4307029582A5042226622 @default.
• W4307029582 hasAuthorship W4307029582A5049876235 @default.
• W4307029582 hasConcept C118487528 @default.
• W4307029582 hasConcept C120665830 @default.
• W4307029582 hasConcept C121332964 @default.
• W4307029582 hasConcept C126322002 @default.
• W4307029582 hasConcept C141071460 @default.
• W4307029582 hasConcept C168563851 @default.
• W4307029582 hasConcept C2776403814 @default.
• W4307029582 hasConcept C2776694085 @default.
• W4307029582 hasConcept C2777235844 @default.
• W4307029582 hasConcept C2777802072 @default.
• W4307029582 hasConcept C2778257484 @default.
• W4307029582 hasConcept C2778749236 @default.
• W4307029582 hasConcept C2781100027 @default.
• W4307029582 hasConcept C44249647 @default.
• W4307029582 hasConcept C50440223 @default.
• W4307029582 hasConcept C61511704 @default.
• W4307029582 hasConcept C71924100 @default.
• W4307029582 hasConcept C82789193 @default.
• W4307029582 hasConcept C95190672 @default.
• W4307029582 hasConceptScore W4307029582C118487528 @default.
• W4307029582 hasConceptScore W4307029582C120665830 @default.
• W4307029582 hasConceptScore W4307029582C121332964 @default.
• W4307029582 hasConceptScore W4307029582C126322002 @default.
• W4307029582 hasConceptScore W4307029582C141071460 @default.
• W4307029582 hasConceptScore W4307029582C168563851 @default.
• W4307029582 hasConceptScore W4307029582C2776403814 @default.
• W4307029582 hasConceptScore W4307029582C2776694085 @default.
• W4307029582 hasConceptScore W4307029582C2777235844 @default.
• W4307029582 hasConceptScore W4307029582C2777802072 @default.
• W4307029582 hasConceptScore W4307029582C2778257484 @default.
• W4307029582 hasConceptScore W4307029582C2778749236 @default.
• W4307029582 hasConceptScore W4307029582C2781100027 @default.
• W4307029582 hasConceptScore W4307029582C44249647 @default.
• W4307029582 hasConceptScore W4307029582C50440223 @default.
• W4307029582 hasConceptScore W4307029582C61511704 @default.
• W4307029582 hasConceptScore W4307029582C71924100 @default.
• W4307029582 hasConceptScore W4307029582C82789193 @default.
• W4307029582 hasConceptScore W4307029582C95190672 @default.
• W4307029582 hasIssue "11" @default.
• W4307029582 hasLocation W43070295821 @default.
• W4307029582 hasLocation W43070295822 @default.
• W4307029582 hasOpenAccess W4307029582 @default.
• W4307029582 hasPrimaryLocation W43070295821 @default.
• W4307029582 hasRelatedWork W1663750035 @default.
• W4307029582 hasRelatedWork W2019435952 @default.
• W4307029582 hasRelatedWork W2145661951 @default.
• W4307029582 hasRelatedWork W2237198389 @default.
• W4307029582 hasRelatedWork W2414742053 @default.
• W4307029582 hasRelatedWork W2543869410 @default.
• W4307029582 hasRelatedWork W2883175396 @default.
• W4307029582 hasRelatedWork W3134869781 @default.
• W4307029582 hasRelatedWork W3190612623 @default.
• W4307029582 hasRelatedWork W2085743381 @default.

• next